4
PIONEER Big Data in Prostate Cancer Platform Opens up to Asian Data Sets
mehr
Storys zum Thema Krebs
-
Sprache:
Englisch
- Medien:
- Zeitraum:
- Zeitraum:Gesamt
Grünenthal and Kyowa Kirin International Announce Successful Completion of Deal to Enter Joint Venture Collaboration
Aachen, Germany and Tokyo, Japan (ots) - - The Joint Venture Collaboration includes a portfolio of 13 brands across six therapeutic areas, with the majority of revenue resulting from pain management medicines - The new enterprise will be branded as Grünenthal Meds. Grünenthal owns a 51 percent majority share and ...
mehrWildDISCO: Visualizing Whole Bodies in Unprecedented Detail
mehrPotentiating Cancer Vulnerability to Ferroptosis: Off-Targeting Effects of DHODH Inhibitors
mehr- 2
CARAMBA: New Hope for Multiple Myeloma Patients
mehr New Approach in Cancer Therapy With Innovative Mechanism-of-Action for Ferroptosis Induction
mehrRHEACELL announces “First Patient In”: EB-Haus in Salzburg, Austria starts pivotal study for stem cell therapy for severe forms of Epidermolysis bullosa that is longed for by those affected
mehrFirst Integrated Single-Cell Atlas of the Human Lung
Can a human organ be mapped on a single-cell level to learn about the functionality of each individual cell? And can we learn how different these cells are from person to person? Helmholtz Munich researchers and their collaborators have taken up this challenge and developed the Human Lung Cell Atlas using artificial intelligence (AI)-based techniques. This atlas elucidates the diversity of single lung cell types and ...
mehrThe Medias Hospital is Raising the Bar for Interventional Oncology as an IASIOS Enrolled Centre
Burghausen/Germany (ots) - The Medias Hospital has officially enrolled in the accreditation program of IASIOS to further ensure highest quality standards in Interventional Oncology as an important aspect of oncological patient care. The Medias Hospital has taken the next step to committing to the highest standards when it comes to interventional oncology (IO) care and ...
mehrDEBIOPHARM LAUNCHES PHASE 1 RESEARCH IN SMALL CELL LUNG CANCER WITH WEE1 INHIBITOR DEBIO 0123 TO OUTSMART DDR IN SMALL CELL LUNG CANCER
Lausanne, Switzerland (ots) - - Debiopharm combines its potent WEE1-inhibitor Debio 0123 with standard-of-care therapy to short-circuit DNA damage repair (DDR) in adults with recurrent or progressive small cell lung cancer (SCLC). - The first patient dosed at Vall d’Hebron Hospital (Barcelona, Spain), was ...
mehrDEBIOPHARM LAUNCHES PHASE 1/2 COMBINATION TRIAL INVESTIGATING BRAIN-PENETRANT SELECTIVE WEE1 INHIBITOR FOR BRAIN CANCER PATIENTS
Lausanne (ots) - - Glioblastomas (GBM) are among the most aggressive and lethal tumors of the central nervous system with a 5-year survival rate of only 6.8%. - Debiopharm is combining its potent, brain penetrant WEE1 inhibitor Debio 0123 with standard of care (SOC) therapy. Debio 0123 hopes to hinder DNA damage ...
mehr- 3
Sysmex Europe distributes MammaTyper®, an advanced breast cancer diagnostic assay, through the European distribution agreement with Cerca Biotech
mehr Genialis Raises $13M to Build Clinical Biomarkers that Predict Patient Response
BOSTON, LAUSANNE & LJUBLJANA, Slovenia (ots) - Debiopharm Innovatoin Fund & Taiwania Capital co-lead financing round for Genialis to propel drug development, diagnostics and treatment planning through AI/ML-enabled platform with a biology-first approach Genialis, a computational precision medicine company unraveling complex biology to find new ways to address disease, ...
mehrDEBIOPHARM ANNOUNCES LAUNCH OF THE PHASE 1/2 GaLuCi™ STUDY FOR ITS CA IX-TARGETED RADIOPHARMACEUTICAL PROGRAM
Lausanne, Switzerland (ots/PRNewswire) - - Debiopharm is developing personalized radiotherapy through a theranostic approach, combining diagnostic imaging (Debio 0328 a gallium-labelled imaging tool) and therapeutic components (Debio 0228, a lutetium-labelled radioligand), thus allowing the pre-identification and ...
mehrDEBIOPHARM ANNOUNCES LAUNCH OF THE PHASE 1/2 GaLuCiTM STUDY FOR ITS CA IX-TARGETED RADIOPHARMACEUTICAL PROGRAM
Lausanne, Switzerland (ots) - - Debiopharm is developing personalized radiotherapy through a theranostic approach, combining diagnostic imaging (Debio 0328 a gallium-labelled imaging tool) and therapeutic components (Debio 0228, a lutetium-labelled radioligand), thus allowing the pre-identification and treatment of ...
mehrThe world's first Extended Isolated Stopflow Limb Infusion (EISLI) to treat osteosarcoma results in complete remission
mehrDEBIOPHARM EXTENDS THEIR DNA DAMAGE REPAIR FOOTPRINT WITH NEW ONCOLOGY PIPELINE ENTRY
Lausanne, Switzerland (ots) - Debiopharm obtains global rights from Novo Nordisk for the development of their ubiquitin-specific protease 1 (USP1) inhibitor Debiopharm (www.debiopharm.com), an independent Swiss-based, biopharmaceutical company aiming to develop tomorrow’s standard-of-care treatments to cure cancer and infectious diseases, today announced having ...
mehr- 2
Free Access to Cancer Research Services - canSERV 1st Call for Proposals
mehr Free Access to Cancer Research Services - canSERV 1st Call for Proposals
Ein DokumentmehrAccord Healthcare marks World Cancer Day 2023 appearing in ITN Business news-style programme Working Together: To Tackle Cancer
London (ots/PRNewswire) - Accord Healthcare (Accord), one of Europe's fastest growing pharmaceutical companies, marks World Cancer Day 2023 today by taking part in news-style programme for ITN Business alongside other partners from industry and the patient community to raise awareness of the importance of working ...
mehrIEVA (Independent European Vape Alliance)
World Cancer Day - Decrease smoking rates with reduced-risk alternatives
Brussels (ots) - 19.7 percent of the EU population are daily smokers. [1] 700,000 people in the EU die each year as a result of smoking and every second smoker dies on average 14 years prematurely. [2] Smoking is the leading cause of preventable cancer, with 27 percent of all cancers attributed to tobacco. [3] The examples of Great Britain (smoking rate: 13.8 percent) ...
mehrDEBIOPHARM APPLIES EXTENDED-RELEASE FORMULATION EXPERTISE TO REDUCE TREATMENT FREQUENCY BURDEN FOR ACROMEGALY & GEP-NET PATIENTS
Lausanne, Switzerland (ots) - - Acromegaly and gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are rare diseases that require life-long chronic treatment. Monthly somatostatin analog (SSA) injections are the standard of care as first-line medical treatment. - Debiopharm is developing Debio 4126, a novel ...
mehrHearing loss company Acousia Therapeutics completes clinical Phase 1 study with its small molecule
Tübingen, Germany (ots) - Hearing loss company Acousia Therapeutics GmbH announced the successful completion of its ACOU085 clinical Phase 1b study today, following the final visit of the last patient treated with the highest ACOU085 dose. ACOU085 is a proprietary small-molecule drug candidate under clinical ...
mehrTechnische Universität München
New X-ray technology can improve Covid-19 diagnosis
TECHNICAL UNIVERSITY OF MUNICHCorporate Communications Center phone: +49 89 289 22798 - email: presse@tum.de - web: www.tum.de Images: https://mediatum.ub.tum.de/1692790 NEWS RELEASE New X-ray technology can improve Covid-19 diagnosis Patient study demonstrates benefits of dark-field X-ray technology A research team at the Technical University of Munich (TUM) has, for the first time, produced dark-field X-ray images of ...
mehrTechnische Universität München
Nanoswitches for tumor targeting
TECHNICAL UNIVERSITY OF MUNICHCorporate Communications Center phone: +49 89 289 22798 - email: presse@tum.de - web: www.tum.de Video: https://www.youtube.com/watch?v=_xXV0mCke1g NEWS RELEASE Nanoswitches for tumor targeting TUM spin-off Plectonic develops antibody-based immunotherapies Plectonic Biotech, a spin-off of the Technical University of Munich (TUM), has developed a nanoswitch that binds immune cells to tumor cells. The goal is to facilitate the development of ...
mehrHearing loss company Acousia Therapeutics to present data for lead candidates ACOU085 & ACOU082 at ARO 2023 MidWinter Meeting February 11–15
Tübingen, Germany (ots) - Acousia Therapeutics GmbH, and its partners from the Translational Hearing Research Group at the Tübingen Hearing Research Center (Department of Otolaryngology, Head and Neck Surgery, University of Tübingen), will present data on its lead candidates — clinical stage ACOU085 and late ...
mehrKlinik für Prostata-Therapie Heidelberg
Focal therapy for prostate cancer: Reliable diagnosis leads to gentle treatment
mehrLandscape of molecular contacts: How the coronavirus SARS-CoV-2 communicates with human cells
mehrTechnische Universität München
Improved monitoring of silicone implants
TECHNICAL UNIVERSITY OF MUNICH Corporate Communications Center phone: +49 89 289 10808 - email: presse@tum.de - web: www.tum.de This text on the web: https://www.tum.de/aktuelles/alle-meldungen/pressemitteilungen/details/verbessertes-monitoring-von-silikonimplantaten Pictures: https://mediatum.ub.tum.de/1687409 NEWS RELEASE Improved monitoring of silicone implants New algorithm for clinical MRI scanners makes breast ...
mehrEuropean Society for Medical Oncology (ESMO)
ESMO 2022 - Great oaks grow from small acorns: oncology is committed to doing its part for sustainability
Paris (ots) - At ESMO 2022, 9-13 September, Paris, France, the premier cancer congress in Europe, which has gathered 28k participants from 167 countries, many discussions will be around sustainability, prevention and novel approaches which could soon become a reality in the clinic. - Late-breaking results elucidate ...
mehr
Vorherige1234Nächste